Auto-injectors Market Report

Increasing patient convenience, the increased prevalence of chronic and lifestyle disorders and technological advancements are driving market expansion. According to the World Health Organization, over 16 billion injections are given globally each year. As a result, the increasing number of injections each year promotes demand for auto-injectors, strengthening the industry. In accordance with the American Hospital Association, over half of all Americans accounting for 133 million suffer from at least one chronic condition. This figure is anticipated to rise to 170 million by 2030. Chronic diseases of various forms have been identified as the primary causes of disability and morbidity globally. The American Cancer Society estimates that approximately 1.9 million new cancer cases will be detected in the United States in 2023. Additionally, Diabetes affects about 537 million individuals aged 20 to 79, as reported by the World Diabetes Federation. The overall number of diabetes is anticipated to reach 643 million by 2030, and 783 million by 2045. As a result, the rise in the number of chronic diseases drives market growth over the forecast period.

Patients and healthcare professionals are increasingly focusing on alternative methods such as as oral, topical and nasal since traditional injectables with vials and needles are invasive and painful. The ideal approach is oral administration since it is simple to administer, quick, cost-effective, safe and acceptable. Needle-free devices also have the advantage of not instilling needle phobia, which is a key barrier to the widespread use of injectable medicine therapies. A research published in the National Library of Medicine found that the majority of children were scared of needles, with prevalence estimates ranging from 20-50% in teenagers to 20-30% in young people. Also, approximately 45% of rheumatoid arthritis patients reported a fear of needles. Patients with rheumatoid arthritis, diabetes and growth hormone deficiency, among other conditions, require weekly injectable treatment with auto-injectors, needle fear is a significant restraint to market growth. Strict regulatory clearances, premium pricing and product recalls are some of the factors that are projected to limit market growth during the forecast period.

Major industry leaders utilize strategies that focus on launching new products, merging with competitors, and purchasing companies to grow their customer base and enhance their range of products. In February 2024, the collaboration between Stevanato Group and Owen Mumford for the Aidaptus auto-injector has seen significant advancements. At Pharmapack, a workshop led by Adam Stops of Stevanato and Richard Harrison of Owen Mumford highlighted innovations in simplifying device development and optimizing glass solutions for auto-injectors. This partnership is poised to enhance the global auto-injector market by integrating cutting-edge design and materials, streamlining production processes, and ultimately improving patient outcomes.

Furthermore, In January 2023, AstraZeneca’s Tezspire (tezepelumab) received a positive opinion from the European Medicine Agency's CHMP for self-administration via a pre-filled pen for severe asthma patients aged 12 and older. This development, stemming from successful PATHFINDER clinical trials, highlights Tezspire’s efficacy and ease of use in both clinical and home locations. The approval highlights a significant advancement in the global auto-injectors market, emphasizing enhanced patient autonomy and streamlined severe asthma management, setting Tezspire apart as a unique biologic without phenotype or biomarker restrictions.

The market for disposable auto-injectors is anticipated to be dominated by North America during the forecast period. Early adoption of technologically improved products and product approvals, as well as the increased prevalence of chronic diseases, all contribute to the region's market growth. The region's market is boosted by a high prevalence of chronic diseases such as diabetes. As per the United States Census Bureau and Asthma and Allergy Foundation of America, the North American auto-injectors market is notably driven by high diabetes prevalence and significant allergy burden. Over 37 million Americans are affected by diabetes, with substantial numbers at risk, highlighting a robust demand for auto-injectors. Additionally, with cities like Dallas and Orlando ranking high in seasonal pollen scores and allergy medication use, the market establishes increased demand. North America commands the largest share in the global auto-injectors market, largely due to these health factors.